NCT05483192 (Dyglomera) is a NA clinical trial of Oral Dyglomera in Body Fat Disorder, sponsored by Gateway Health Alliance.

Who is sponsoring NCT05483192?

NCT05483192 is sponsored by Gateway Health Alliance.

What drugs are being tested in NCT05483192?

Interventions in NCT05483192: Oral Dyglomera.

What condition does NCT05483192 study?

NCT05483192 studies Body Fat Disorder.

Is NCT05483192 still recruiting?

NCT05483192 is currently completed. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05483192: Dyglomera

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Oral Dyglomera™ on Body Fat and Blood Lipids of Overweight and Obese Adults

Completed NA Last updated 2 August 2022

What this trial tests

NA trial testing Oral Dyglomera in Body Fat Disorder in 120 participants. Completed in 18 June 2021.

Timeline

12 February 2021

Primary endpoint
12 June 2021

18 June 2021

Quick facts

Lead sponsor	Gateway Health Alliance
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	12 February 2021
Primary completion	12 June 2021
Estimated completion	18 June 2021
Sites	1 location across India

Drugs / interventions tested

Oral Dyglomera

Conditions studied

Body Fat Disorder — all drugs for Body Fat Disorder →

Sponsor

Gateway Health Alliance

Who can join

Adults 19 to 65, any sex, with Body Fat Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The extract of Dichrostachys glomerata (DyglomeraTM), has been reported to be effective in weight reduction in obese patients with metabolic syndrome. This plant has been shown to have many biological properties and has been reported to have no toxic or adverse side effects in animals. The purpose of this human study was to prove that the effect of reducing body fat percentage (%) after 12 weeks of intake was superior to that of the control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483192 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gateway Health Alliance
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing